Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of t...

Full description

Saved in:
Bibliographic Details
Published in:Quality of life research 2021-07, Vol.30 (7), p.2033-2043
Main Authors: Matza, Louis S., Cutts, Katelyn N., Stewart, Katie D., Norrbacka, Kirsi, García-Pérez, Luis-Emilio, Boye, Kristina S.
Format: Article
Language:English
Subjects:
Diabetes
GLP-1 receptor agonists
Medicine
Medicine & Public Health
Preferences
Public Health
Quality of Life Research
Sociology
UTILITIES
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of type 2 diabetes (T2D). Methods Participants with T2D in the UK reported preferences and valued four health state vignettes in time trade-off utility interviews. The vignettes had identical descriptions of T2D but differed in treatment process: (1) daily simple oral treatment (tablets without administration requirements), (2) daily oral semaglutide (with administration requirements per product label), (3) weekly dulaglutide injection, (4) weekly semaglutide injection. Results Interviews were completed by 201 participants (52.7% male; mean age = 58.7). Preferences between treatment processes varied widely. Mean utilities were 0.890 for simple oral, 0.880 for oral semaglutide, 0.878 for dulaglutide injection, and 0.859 for semaglutide injection (with higher scores indicating greater preference). All pairwise comparisons found statistically significant differences between utilities (p 
ISSN:0962-9343
1573-2649
DOI:10.1007/s11136-021-02808-2